DUNDEE, Scotland, Jan. 13, 2025 /PRNewswire/ -- Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its ...

I am excited to be able to leverage my knowledge and experience in drug discovery and development alongside the world-leading E3 ligase expertise offered by the Outrun team and its academic ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

Importantly, AUCell analysis revealed that CHIP E3 ubiquitin ligase activity deficiency affected ubiquitin-mediated proteolysis, ultimately increasing the level of intracellular cAMP. The activation ...